These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23921678)

  • 21. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
    Torres A
    Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
    Sinha V; Zhao P; Huang SM; Zineh I
    Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Food and Drug Administration's paternalism.
    Somberg JC
    Am J Ther; 2010; 17(6):533-4. PubMed ID: 21060255
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of drug clearance in children.
    Foissac F; Bouazza N; Valade E; De Sousa Mendes M; Fauchet F; Benaboud S; Hirt D; Tréluyer JM; Urien S
    J Clin Pharmacol; 2015 Jul; 55(7):739-47. PubMed ID: 25721251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular biomarkers: a US FDA effort.
    Hong H; Goodsaid F; Shi L; Tong W
    Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of high-dose carboplatin in children and adults.
    Lindauer A; Eickhoff C; Kloft C; Jaehde U
    Ther Drug Monit; 2010 Apr; 32(2):159-68. PubMed ID: 20110851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
    Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022.
    Tunehag KR; George B; Samuels S; Vo K; Arya V; Abulwerdi G; Burckart GJ
    J Clin Pharmacol; 2024 Jun; 64(6):697-703. PubMed ID: 38294346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tricky FDA debate: should a risky drug be approved again?
    Mathews AW; Westphal SP
    Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
    [No Abstract]   [Full Text] [Related]  

  • 34. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults.
    Knibbe CA; Zuideveld KP; Aarts LP; Kuks PF; Danhof M
    Br J Clin Pharmacol; 2005 Jun; 59(6):705-11. PubMed ID: 15948935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
    Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
    Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
    Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
    Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
    Mahmood I
    J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
    Hart B; Lundh A; Bero L
    BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.